FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAbbVie Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ABBV
AbbVie Inc. Stock AnalysisComprehensive stock analysis for AbbVie Inc. (ABBV) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisABBV
ABBV
AbbVie Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ABBV
  1. Home
  2. Stocks
  3. AbbVie Inc.

AbbVie Inc.

🇺🇸ABBV•NYSE

AbbVie Inc.

🇺🇸ABBV•NYSE
Market cap
$520.86B
Sentiment

Your view on ABBV

Mkt Cap
$520.86B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About AbbVie Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Robert A. Michael CPA
Headquarters
1 North Waukegan Road, North Chicago, IL, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Robert A. Michael CPA
Headquarters
1 North Waukegan Road, North Chicago, IL, US
Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.

The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.

In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for AbbVie Inc. from FRC's valuation model, read against the market price. ABBV last traded at $294.67, 50.6× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for AbbVie Inc.. Starting points for AbbVie Inc.: P/E 50.6, EPS $5.84, beta 0.28 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for AbbVie Inc.. AbbVie Inc. paid $6.92 per share over the last year — a 2.3% yield at the current $294.67 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for AbbVie Inc.. Trailing twelve-month EPS for AbbVie Inc. stands at $5.84. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$309.59

average of 17 firms, last 12 months

 

$309.59

Low $235.00

Median $315.00

High $349.00

 

Analyst Ratings

Buy25 firms, last 12 months
  • Strong Buy0
  • Buy21
  • Hold4
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$3.89$3.44$14.01$16.26
Low estimate$3.79$3.38$13.93$15.54
High estimate$4.01$3.49$14.17$16.63
No. of analysts1361516
Year-ago EPS$2.71$2.65$2.371—
Growth+43.6%+29.9%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$18.35B$16.53B$67.73B$73.84B
Low estimate$18.30B$16.24B$67.53B$71.78B
High estimate$18.49B$17.08B$67.96B$75.26B
No. of analysts1041919
Year-ago revenue$16.62B$15.00B$61.16B—
Growth+10.4%+10.2%+10.7%—
Recent analyst actions15 rating and price-target changes, latest Nov 18, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, TheStreet; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for AbbVie Inc.. AbbVie Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ABBV18 companies · 8 funds
Compare ABBV with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • AMGNAmgen Inc.Drug Manufacturers - General$250.1B
  • AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
  • BMYBristol-Myers Squibb CompanyDrug Manufacturers - General$128.6B
  • GSKGSK plcDrug Manufacturers - General$101.3B
  • JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
  • LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
  • MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
  • NVSNovartis AGDrug Manufacturers - General$302.6B

More Drug Manufacturers - General companies

  • AMRNAmarin Corporation plcNASDAQ$234M
  • BAYRYBayer AGOTC$49.0B
  • BIIBBiogen Inc.NASDAQ$37.2B
  • CHGCFChugai Pharmaceutical Co., Ltd.OTC$105.3B
  • CHGCYChugai Pharmaceutical Co., Ltd.OTC$110.0B
  • CHJTFCSPC Pharmaceutical Group LimitedOTC$15.8B
  • CSPCYCSPC Pharmaceutical Group LimitedOTC$14.6B
  • DSKYFDaiichi Sankyo Company, LimitedOTC$34.1B
  • DSNKYDaiichi Sankyo Company, LimitedOTC$36.2B
  • FRE.AXFirebrick Pharma LimitedASX

ETFs holding AbbVie Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.80%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.72%
  • IVViShares Core SP 500 ETF$852.9B in assets0.82%
  • SPYState Street SPDR S&P 500 ETF Trust$818.5B in assets0.82%
  • IYHiShares US Healthcare ETF$4.7B in assets7.56%
  • HDViShares Core High Dividend ETF$16.2B in assets6.91%
  • VHTVanguard Health Care ETF$19.1B in assets6.73%
  • FHLCFIDELITY MSCI HEALTH CARE INDEX ETF$4.0B in assets6.70%

Largest holders first, then the funds most concentrated in ABBV.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold AbbVie Inc., and how their positions are changing. At a $520.86B market value, institutional positions materially move AbbVie Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by AbbVie Inc. executives and directors. Shares of AbbVie Inc. have traded between $164.39 and $244.81 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming AbbVie Inc.. AbbVie Inc. is a $520.86B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming AbbVie Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for AbbVie Inc.. Coverage tracks AbbVie Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of AbbVie Inc.

ABBV Analysis
Weak
Past4
Growth2
Health1
Profit1
Value1

News

Latest Market News